Início
Explorar
nav.journalClub
Tendências
Mais
synapse
⌘+K
Idioma
Português
Português
Interferon Alpha-2a as Treatment for Primary Acquired Melanosis with Atypia (PAMwA) and for PAMwA surrounding conjunctival melanoma | Synapse
March 3, 2026
Interferon Alpha-2a as Treatment for Primary Acquired Melanosis with Atypia (PAMwA) and for PAMwA surrounding conjunctival melanoma
DV
Daniela Vaisman
Hadassah Medical Center
JP
Jacob Pe’er
Hebrew University of Jerusalem
ME
Maya Eiger-Moscovich
Hadassah Medical Center
See all
Key Points
Interferon alpha-2a treatment shows promise in managing primary acquired melanosis with atypia.
Remarkably, 75% of treated cases exhibited significant reduction in atypical melanocytic cells within three months.
This observational study evaluates treatment efficacy based on tumor microenvironment assessments and clinical observations.
Findings highlight the potential for interferon alpha-2a in improving outcomes for patients with PAMwA and related melanoma.
Mark Helpful
Like
Save
Bookmark
Relay
Share
Mark Helpful
Like
Save
Bookmark
Relay
Share
Cite This Study
Copy
Vaisman et al. (Thu,) studied this question.
synapsesocial.com/papers/69a75d6bc6e9836116a2772b
https://doi.org/https://doi.org/10.1016/j.ajo.2026.01.029